BS EN 1040:2005 Basic Bactericidal Activity Testing for Chemical Disinfectants
Airmid Healthgroup provides independent, ISO/IEC 17025-accredited BS EN 1040:2005 testing services — delivering quantitative basic bactericidal efficacy data for disinfectant and antiseptic manufacturers seeking European regulatory compliance, BPR submissions, and independently validated product claims.
The Foundation Standard for Bactericidal Claims in Europe
BS EN 1040:2005 is the quantitative suspension test for evaluating the basic bactericidal activity of chemical disinfectants and antiseptics. It is one of the most fundamental standards in the European disinfectant testing framework and forms the basis for demonstrating bactericidal efficacy under clean conditions without interfering substances.
Scope of BS EN 1040:2005
BS EN 1040:2005 specifies a basic quantitative suspension test for the evaluation of bactericidal activity of chemical disinfectants and antiseptics. It is a Phase 1 test — meaning it is conducted under the simplest, cleanest conditions to establish basic bactericidal performance before more complex Phase 2 tests (such as BS EN 1276) are conducted under conditions simulating real-world use.
The standard uses two representative test organisms — Pseudomonas aeruginosa and Staphylococcus aureus — covering both Gram-negative and Gram-positive bacteria to provide a broad assessment of basic bactericidal performance.
BS EN 1040:2005 Testing Protocol
How the BS EN 1040:2005 Test Works
- Product Preparation: The disinfectant is prepared at the intended use concentration and assessed for suitability under Phase 1 conditions — without the addition of interfering substances.
- Bacterial Suspension Preparation: Standardised suspensions of Pseudomonas aeruginosa and Staphylococcus aureus are prepared and quantified to ensure a defined starting concentration of viable bacteria.
- Contact Exposure: The product is mixed with the bacterial suspension at 20±1°C for 5 minutes under clean, interference-free conditions.
- Neutralisation: The reaction is stopped by adding a neutralising agent immediately after the contact period — preventing any further disinfectant activity during analysis.
- Enumeration: Surviving bacteria are serially diluted and plated on nutrient agar. Colony forming units (CFUs) are counted after incubation to determine the number of viable bacteria remaining.
- Log Reduction Calculation: Bactericidal efficacy is expressed as the log₁₀ reduction in viable bacteria compared to the untreated control. A ≥5 log₁₀ reduction is required to pass.
Why BS EN 1040:2005 Testing Matters
BPR Regulatory Foundation
As a Phase 1 standard, BS EN 1040 forms the foundational layer of the European BPR testing framework — establishing basic bactericidal performance before more complex Phase 2 tests are conducted.
Early-Stage Product Screening
BS EN 1040 is commonly used as a cost-effective screening test during product development — identifying effective formulations before committing to full Phase 2 testing programmes.
Independent Validation
Third-party validated BS EN 1040 data supports basic bactericidal claims, strengthens regulatory dossiers, and builds credibility with procurement teams and certification bodies.
Integrated Testing Programme
BS EN 1040 is typically conducted alongside BS EN 1276 (Phase 2 bactericidal), BS EN 1275 (fungicidal), and BS EN 13610 (virucidal) to build a comprehensive antimicrobial profile.
Products That Can Be Tested
- Household and commercial disinfectants and sanitisers
- Healthcare and hospital-grade disinfectants
- Food contact surface disinfectants
- Industrial and manufacturing facility disinfectants
- Hand hygiene and antiseptic formulations
- Concentrated products and ready-to-use formulations
- Novel or early-stage disinfectant formulations under development
Accreditation & Third-Party Validation
Airmid Healthgroup’s ISO/IEC 17025-accredited, GLP-compliant laboratory delivers independently validated results accepted by the EU BPR authority, EPA, and FDA. All testing is conducted in strict accordance with cGLP regulations.
On passing BS EN 1040:2005 testing, products can be labelled as independently tested by Airmid Healthgroup to BS EN 1040:2005 standards — supporting basic bactericidal claims in marketing materials, regulatory dossiers, and procurement specifications.
Request a Quote for BS EN 1040:2005 Testing
Contact Airmid Healthgroup to discuss your bactericidal testing requirements and receive a tailored quote.
Frequently Asked Questions
What is the difference between BS EN 1040 and BS EN 1276?
BS EN 1040 is a Phase 1 test conducted under clean, interference-free conditions — establishing the basic bactericidal potential of a product. BS EN 1276 is a Phase 2 test conducted with interfering substances (bovine serum albumin under clean conditions, or BSA plus erythrocytes under dirty conditions) to simulate real-world use scenarios. Most regulatory submissions require both Phase 1 and Phase 2 data, so BS EN 1040 and BS EN 1276 are typically conducted together.
Why are both Gram-positive and Gram-negative bacteria used?
Staphylococcus aureus (Gram-positive) and Pseudomonas aeruginosa (Gram-negative) represent two structurally different types of bacteria with different susceptibilities to disinfectants. Using both ensures the test captures a broad spectrum of bactericidal performance rather than efficacy against a single organism type.
Can BS EN 1040 be used for product development screening?
Yes. BS EN 1040 is widely used as an early-stage screening test during formulation development — helping identify which product concentrations and formulations demonstrate sufficient basic bactericidal activity before investing in a full Phase 2 testing programme. Airmid can support product development teams at all stages from early R&D through to final regulatory submission.
What log reduction is required to pass BS EN 1040?
A ≥5 log₁₀ reduction (99.999% kill rate) in viable bacteria against both test organisms within 5 minutes is required for a basic bactericidal claim under BS EN 1040:2005.
What will I receive after BS EN 1040:2005 testing?
You will receive a full GLP-compliant test report detailing the methodology, test conditions, log₁₀ reduction calculations for both test organisms, pass/fail conclusion, and all raw data — suitable for BPR dossiers, regulatory submissions, and marketing claims.
Related Tests and Services
- BS EN 1276:2019 — Phase 2 Bactericidal Activity
- BS EN 1275 — Fungicidal / Yeasticidal Activity
- BS EN 13704:2018 — Sporicidal Activity
- BS EN 13697:2015 — Non-Porous Surface Bactericidal/Fungicidal Activity
- BS EN 13610 — Virucidal Activity
- BS EN 13727 — Bactericidal Activity in the Medical Area
- Microbiology Laboratory Services
- Claims Verification Services
- Customised Testing Projects
